GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
What's Next for Alzheimer's Treatment? Some Scientists Are Betting on GLP-1 Drugs
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
28 benefits, 16 risks: How popular GLP-1 weight loss drugs reshape human health – for better and worse
A new study reveals that popular diabetes and weight loss medications like Ozempic and Wegovy may offer unexpected health benefits, from reducing addiction risk to protecting against Alzheimer’s disease.
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
Benefits and risks of GLP-1 drugs and criteria for dementia diagnosis
In today’s health headlines, the 175 health benefits and risks of taking GLP-1 drugs. Also, many older adults don’t realize they meet the criteria for a dementia diagnosis. Finally, what are the brain effects of short video watching on TikTok and reels?
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions,
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Medscape4h
A Guide for Discussing GLP-1s as Obesity Treatments
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...
Medscape1d
GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
FiercePharma2h
As Super Bowl nears, TV data show GLP-1 game day ads enjoyed a big year
Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...
STAT1h
Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...